Challenges in implementing 2021 WHO CNS tumor classification in a resource-limited setting.

ABSTRACT:

Background

The 2021 World Health Organization classification of Central Nervous System tumors (CNS5) includes molecular biomarkers in the necessary diagnostic criteria for many tumors. Identifying these markers often requires next-generation sequencing (NGS) and/or DNA methylation profiling, presenting challenges in diagnosing these tumors in low or middle-income countries (LMICs) and other resource-limited settings. Here, we will illustrate the real-world scope of the problem by presenting a neuropathologist's experience with implementing the CNS5 criteria in an academic medical center in Karachi, Pakistan.

Methods

CNS tumor biopsies received by a single neuropathologist (AG) in Karachi during a 6-month period (October 2022 to March 2023) were included in the study. Routine

SUBMITTER: Gilani A 

PROVIDER: S-EPMC12137215 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature